BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc.
(NYSE American: AZTR), a clinical-stage biopharmaceutical company
focused on developing innovative therapies for precision
dermatology, announced today that Travis
Whitfill, COO, will present an overview of the Company at
the H.C. Wainwright 25th Annual Global Investment Conference, being
held from September 11-13, 2023.
Company management will also be participating in one-on-one
meetings during the conference.
The on-demand presentation will be available for viewing
beginning September 11 at
7:00 a.m. ET. An archived replay of
the presentation will be available on the Company's website
immediately following the conference and for at least 90 days
thereafter.
H.C. Wainwright 25th
Annual Global Investment Conference – September 11-13,
2023
|
Format:
|
|
Azitra Inc., Corporate
Presentation
|
Date/Time:
|
|
Available on-demand
Monday, September 11, 2023 at 7:00 AM ET
|
Participant:
|
|
Travis Whitfill, Chief
Operating Officer
|
Location:
|
|
Lotte New York Palace
Hotel, New York City, NY
|
Webcast Link: Register
here
|
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision
dermatology using engineered proteins and topical live
biotherapeutic products. The Company has built a proprietary
platform that includes a proprietary, microbial library of unique
bacterial strains that can be screened for therapeutic
characteristics and lead drug candidates. The platform is augmented
by an artificial intelligence and machine learning technology that
analyzes, predicts and helps screen the Company's library of
strains for drug like molecules. The Company's initial focus is on
the development of genetically engineered strains of Staphylococcus
epidermidis, or S. epidermidis, which the Company considers to be
an optimal therapeutic candidate species for engineering of
dermatologic therapies. For more information, please visit
https://azitrainc.com/.
Forward Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on the Company's
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the section
titled "Risk Factors" in the final prospectus dated
June 15, 2023 relating to our initial
public offering filed with the SEC on June
21, 2023. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no duty to update such information except as required under
applicable law.
CONTACT
Norman
Staskey
staskey@azitrainc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azitra-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301911795.html
SOURCE Azitra, Inc.